There are a significant number of patients receiving drug-eluting stents and besides, require oral anticoagulation. The combination of anticoagulants, aspirin, and clopidogrel greatly increases the rate of bleeding, because of this, the time of the triple scheme should be as short as possible. The aim of this study was to compare the triple therapy for...
The aim of this study was to compare angioplasty guided by fractional flow reserve (FFR) versus conventional angiography in bifurcations treated with provisional stent technique for lateral branch. The study included patients with bifurcations 1,1,1 or 0,1,1 of Medina classification and lateral branches, superior to 2.5 mm. 2nd generation pharmacological stents were used. After stent...
This prospective, multicenter, randomized trial compared the paclitaxel-eluting balloon versus everolimus-eluting stent to treat patients with in-stent restenosis. 309 patients were included in total (154 received the drug-eluting balloon, and 155 received the everolimus-eluting stent). There were no differences in the characteristics of both groups. At one year the rate of cardiac death, myocardial infarction...
This study evaluated the performance of Nobori biolimus bio-absorbable polymer stent in real-world patients. A total of 3067 consecutive patients followed up to 5 years were included. The rate of target lesion (composite of cardiac death, myocardial infarction and target lesion revascularization) was 3.9% at one year and 5.1% at 2 years. Long-term clinical performance...
TRYTON is a cobalt chromium device specifically dedicated for bifurcation lesions to be implanted in the side branch. Circumflex artery is the major lateral branch fund the coronary tree. Between 2008 and 2011 this work included 52 patients with left main coronary unprotected lesions who underwent angioplasty with drug-eluting stent in the coronary trunk left...
Previous studies suggest the excellent performance of the bioactive coated stent TITAN 2 compared with drug-eluting stents (DES). The aim of the study was to evaluate the results of this device in patients undergoing both ST segment elevation and without ST segment elevation acute coronary syndrome. A total of 1066 patients were included, of whom...
This study randomized 2:1 – 2707 patients to biolimus eluting stent with biodegradable polymer versus everolimus eluting stent with permanent polymer. At one year, the results were similar demonstrating the biolimus eluting stent noninferiority. At three years cardiac death, myocardial infarction and target vessel revascularization rates remained similar with 11% for biolimus eluting stent and...
The aim of this study was to evaluate the performance of the sirolimus eluting stent with bio -absorbable polymer (MiStent SES) compared with zotarolimus eluting stent with permanent polymer (Endeavor). This 2:1 randomized, multicenter study included 183 patients with the primary objective of evaluating the late lumen loss between the MiStent and Endeavor a two...
The last results of the SORT OUT V submitted in PCR 2012 showed that biolimus eluting stent with biodegradable polymer was not able to reach the non-inferiority versus sirolimus eluting stent with permanent polymer. Results to 3 years are now available, and the new device reached the non-inferiority with a MACE rate of 11.2% for...
This study compared the clinical and angiographic results of the use of the provisional stent technique versus the 2 stents technique (TRYTON device at the side branch) in true bifurcations. The study with non-inferiority design, randomized 704 patients in total to drug-eluting stent in the main branch plus the TRYTON device in the side branch...